Abstract: The present invention relates to a pharmaceutical composition and a therapeutic combination comprising obicetrapib and ezetimibe, which may be used in the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia and wherein said subjects are partially or completely intolerant to statins.

Abstract: The present invention relates to the treatment of cardiovascular disease, more particularly to the treatment of subjects suffering from or at risk of suffering from atherosclerotic cardiovascular disease that are hypo-responsive to HIS treatment. The present inventors have found that HIS hypo-responders show remarkable improvements in their blood lipid profiles when their statin therapy is combined with treatment with the CETP inhibitor obicetrapib. In a general aspect, the present invention thus provides methods of treating subjects that are hypo-responsive to high intensity statin (HIS) therapy, said method comprising the administration of a composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof.